EP2619591A2 - Composés pour le diagnostic de maladies neurodégénératives sur l'épithélium olfactif - Google Patents

Composés pour le diagnostic de maladies neurodégénératives sur l'épithélium olfactif

Info

Publication number
EP2619591A2
EP2619591A2 EP11804933.7A EP11804933A EP2619591A2 EP 2619591 A2 EP2619591 A2 EP 2619591A2 EP 11804933 A EP11804933 A EP 11804933A EP 2619591 A2 EP2619591 A2 EP 2619591A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
alkenyl
alkynyl
coo
enantiomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11804933.7A
Other languages
German (de)
English (en)
Inventor
Boris Schmidt
Daniel Kieser
Alexander BOLÄNDER
Jochen Herms
Roland Hans Heyny-Von Haussen
Jiamin GU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Maximilians Universitaet Muenchen LMU
Technische Universitaet Darmstadt
Klinikum Darmstadt GmbH
Original Assignee
Ludwig Maximilians Universitaet Muenchen LMU
Technische Universitaet Darmstadt
Klinikum Darmstadt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Maximilians Universitaet Muenchen LMU, Technische Universitaet Darmstadt, Klinikum Darmstadt GmbH filed Critical Ludwig Maximilians Universitaet Muenchen LMU
Publication of EP2619591A2 publication Critical patent/EP2619591A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Definitions

  • the present invention describes compounds having affinity for the A ⁇ protein, for ⁇ -synuclein and / or for tau-PHF aggregates, which are suitable as preferably fluorescent probes for the in vivo diagnosis of neurodegenerative diseases, e.g. Alzheimer's disease and Parkinson's disease.
  • the compounds are characterized by suitable physicochemical properties (such as excitation wavelength, emission wavelength, Stokes shift, extinction) as well as high affinity and selectivity to the target proteins.
  • the present invention relates to the use of such compounds for diagnostic purposes and to a method for the diagnosis of neurodegenerative diseases.
  • Alzheimer's or Parkinson's disease brings considerable benefits to the patient in therapy.
  • the reliable diagnosis of Alzheimer's disease is currently only possible by postmortem microscopy.
  • CT Computed Tomography
  • MRI Magnetic Resonance Imaging
  • PET Positron Emission Tomography
  • WO2009155017 discloses radiopharmaceutical compositions which have a high affinity for amyloid plaques and are detected by positron emission tomography.
  • WO2007136996 describes cyanine dyes which are used for the labeling of biomolecules, eg for the in vivo diagnosis of cancer.
  • US20020133019 discloses thioflavine derivatives for ante-mortem in vivo diagnosis of, among others, Alzheimer's disease. Labeled thioflavins bind to amyloid plaques and are detected by gamma imaging, MRI or NMR spectroscopy.
  • CSF cerebrospinal fluid
  • An object of the present invention is to provide suitable diagnostic probes for the detection of neurodegenerative diseases, which can be detected via an optical detection method on the olfactory epithelium and / or bulb Olfactorius.
  • the present invention solves this problem by the use of certain compounds for the diagnosis of neurodegenerative diseases.
  • these compounds have at least three of the following properties a) -f):
  • TPSA topological polar surface area
  • Butadiene voltage of alkylated vinyl aromatic be induced.
  • Particularly preferred compounds or probes are aromatic molecules which have a ⁇ -electron system extended over at least two aromatic rings or aromatic ring systems.
  • compounds of the following classes of substances have three or more of the aforementioned properties, so that the present invention provides for the preparation of arylaminothiazoles, 2H-indol-2-ylidene-1-propen-1-yl-indolium cations, benzothiazolylidene-1-propenylbenzothiazolium cations, Benzoxazolylidene-1-propenyl-benzoxazolium cations, 4,6-divinylpyrimidines, 3,6-divinylpyridazines, 2,5-divinylpyrazines, [4- (1, 3-benzothiazol-2-yl) phenyl] hydrazones and / or diaryl ureas, which have an affinity for the A ⁇ protein, ⁇ -synuclein and / or tau-PH F aggregates and are therefore suitable for the diagnosis of neurodegenerative diseases.
  • Compounds of the class of arylaminothiazoles include compounds which
  • X, Y, Z independently of one another denote carbon or nitrogen and
  • R 1, R 2, R 3, R 4 independently of one another Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 4 -C 6 -Alkeninyl, C 3 -Cio cycloalkyl , thioalkyl, alkoxy, Ci-C 6 alkanoyl, C 6 -C 16 - aryl, C 6 -Ci6-heteroaryl, Ci-C 6 haloalkyl, C ⁇ -Ce-haloalkenyl, C 2 -C 6 -Ha oalkinyl!
  • divinyl aromatics more preferably divinyl nitrogen heteroaromatics, and most preferably divinyl pyrimidines, divinyl pyridines, divinyl pyrazines, divinyl pyridazines and divinyl triazines.
  • Ar represents one of the following cyclic, heterocyclic, aromatic or heteroaromatic radicals:
  • X means carbon or nitrogen
  • R 1, R 2, R 3 and R 4 are independently 6 -alkyl, C 2 -C 6 alkenyl, C 2 -C 6 - alkynyl, C 4 -C 6 -Alkeninyl, C 3 -C 0 cycloalkyl, Thioalkyl, alkoxy, CC 6 alkanoyl, C 6 -C 6 aryl, C 6 -C 16 heteroaryl, Ci-C 6 -Ha!
  • Ar represents one of the following cyclic, heterocyclic, aromatic or heteroaromatic radicals:
  • X means carbon or nitrogen
  • R 1, R 2 and R 3 independently of one another d-Ce-alkyl, C 2 -C 6 alkenyl, C 2 -C 6 -A! Kinyl, C 4 -C 6 -Alkeninyl, C 3 -C 0 cycloalkyl, Thioalkyl, alkoxy, C 1 -C 6 -alkanoyl, C 6 -C 6 - Aryl, C 6 -C 6 -heteroaryl, C 1 -C 6 -haloalkyl, C 2 -C 6 -haloalkenyl, C 2 -C 6 -haloalkynyl p C 4 -C 6 -haloalkeninyl, C 3 -C 10 -halocycloalkyl, -H, -OH, -OCH 3, -OC 2 H 5, -OCF3, -OC2F5, -NH 2, -N (CH 3) 2, -N (C 2 H 5) 2,
  • Compound compounds of the [4- (1,3-benzothiazol-2-yl) phenyl] hydrazones include compounds which preferably have the following general structure:
  • Ar represents one of the following cyclic, heterocyclic, aromatic or heteroaromatic radicals:
  • X means carbon or nitrogen
  • R, R 2 and R 3 independently of one another 6 -alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 4 -C 6 -Alkeninyl, C 3 -C 0 cycloalkyl, thioalkyl, alkoxy, Ci-C 6 alkanoyl, C 6 -C 6 - aryl, C 6 -Ci6-heteroaryl, dC 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 haloalkynyl, C 4 -C 6 -Haloalkeninyl , C 3 -C 10 -halocycloalkyl, -H, -OH, -OCH 3 , -OC 2 H 5 , -OCF 3 , -OC 2 F 5, -NH 2 , -N (CH 3 ) 2 , -N (C 2 H 5 )
  • Compounds of the class of 3,6-divinylpyridazines include compounds which preferably have the following general structure:
  • Ar represents one of the following cyclic, heterocyclic, aromatic or heteroaromatic radicals:
  • X means carbon or nitrogen
  • R 1, R 2 and R 3 independently of one another CC 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 4 -C 6 -Alkeninyl, C 3 -C 0 cycloalkyl, thioalkyl, alkoxy, C 1 -C 6 -alkanoyl, C 6 -C 16 - Aryl, C 6 -C 16 -heteroaryl, -C 6 haloalkyl, C 2 -C 6 haloalkenyl, C 2 -C 6 -Haloalkiny !, C 4 -C 6 -Haloalkeninyl, C 3 -C 0 halocycloalkyl, -H , -OH, -OCH 3 , -OC 2 H 5 , -OCF 3, -OC 2 F 5 , -NH 2> -N (CH 3 ) 2 , -N (C 2
  • Compound compounds of the diaryl ureas include compounds which preferably have the following general structure:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 independently of one another are CC 6 alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 - alkynyl, dC 6 -Alkeninyl, C 3 -C 0 cycloalkyl, thioalkyl, alkoxy, Ci-C 6 alkanoyl, C 6 -C 16 aryl, C 6 -C 6 -heteroaryl , C 1 -C 6 -haloalkyl, C 2 -C 6 -haloalkenyl, C 2 -C 6 -haloalkynyl, C 4 -C 6 -haloalkeninyl, C 3 -C 10 -halocycloalkyl, -H, -OH, -OCH
  • Compounds of the class of 2H-indol-2-ylidene-1-propene-1-yl indolium cations, benzothiazolylidene-1-propenyl benzothiazolium cations and benzoxazolylidene-1-propenyl benzoxazolium cations include compounds which preferably have the following general structure:
  • R is hydrogen, -F, - Cl, -Br, -I, -NO 2 , alkoxy;
  • X represents -Cl, -Br, -I, -OTs, -OMs;
  • Y is O, S, CR 1 R 2 ;
  • R 1 and R 2 are independently -CH 3 or -C 2 H 5 ;
  • Z is O or CH 2 ;
  • n 0, 1, 2 or 3.
  • d-Ce-alkyl means: -CH 3 , -C 2 H 5 , -C 3 H 7 , -CH (CH 3 ) 2 , -C 4 H 9, -CH 2 -CH (CH 3 ) 2 , -CH (CH 3 ) -C 2 H 5 , -C (CH 3 ) 3 , -C 5 Hn, -CH (CH 3 ) -C 3 H 7 , -CHR-CH (CH 3 ) -C 2 H 5 , -CH (CH 3 ) -CH (CH 3 ) 2 ,
  • -C CC 4 H 9 , -C 2 H 4 -CH (CH 3 ) -C CH, -CH 2 -CH (CH 3 ) -CH 2 -CECH,
  • thioalkyl means -S-C 1 -C 6 -alkyl, wherein C 1 -C 6 -alkyl has the meaning given above.
  • the following radicals are preferred: -SC 2 H 5 , -S-CH 3 , -SC 3 H 7J -S-CH (CH 3 ) 2, -SC 4 H 9 , -S-CH 2 -CH (CH 3 ) 2 , -S-CH ⁇ CH 3 ) -C 2 H 5 , -SC (CH 3 ) 3 and -SC 5 Hn.
  • Particularly preferred are -S-CH 3 , -SC 2 H 5 , -SC 3 H 7 , -S-CH (CH 3 ) 2 and -SC (CH 3 ) 3 .
  • C 1 -C 6 haloalkyl means a C 1 -C 6 alkyl group containing at least one halogen atom selected from fluoro, chloro, bromo, iodo.
  • the groups are -CH 2 F, -CHF 2 , -CF 3 , -CH 2 Cl, -CH 2 Br, -CH 2 I, -CH 2 -CH 2 F, -CH 2 -CHF 2 , -CH 2 -CF 3 , -CH 2 -CH 2 Cl, -CH 2 -CH 2 Br and -CH 2 -CH 2 I.
  • C 2 -C 6 haloalkenyl means a C 2 -C 6 alkenyl group which contains at least one halogen atom selected from fluorine, chlorine, bromine, iodine.
  • C 2 -C 6 Haloalkynyl means a C 2 -C 6 alkynyl group containing at least one halogen atom selected from fluorine, chlorine, bromine, iodine.
  • C 4 -C 6 -Haloalkeninyl represents a C 4 -C 6 -Alkeninyl group which contains at least one halogen atom selected from fluorine, chlorine, bromine, iodine and C 3 -C halocycloalkyl 0 represents a C 3 -Cio- Cycloalkyl group containing at least one halogen atom selected from fluorine, chlorine, bromine, iodine.
  • alkyloxy or "alkoxy” means -O-Ci-Ce-alkyl, wherein d- C 6 alkyl has the meaning given above.
  • the following Ci-C 6 alkoxy groups are preferred: -0-CH3, -0-C 2 H 5, -O-C3H7, -0-CH (CH 3) 2, -O-C4H9, -O- CH 2 -CH (CH 3 ) 2 , -O-CH (CH 3 ) -C 2 H 5 , -O-C (CH 3 ) 3 and -O-C 5 H 11.
  • Particularly preferred are -0-CH3, -0-C 2 H 5, -O-C3H7, -O-CH (CH 3) 2 and -0-C ⁇ CH3).
  • -CO-CH 3 Preference is given to -CO-CH 3 , -CO-C 2 H 5 , -CO-C 3 H 7 , -CO-CH (CH 3 ) 2 , -CO-C 4 H 9, -CO-CH 2 -CH (CH 3 ) 2 , -CO-CH (CH 3 ) -C 2 H 5 , -CO-C (CH 3 ) 3 and -CO-C 5 Hn.
  • Particularly preferred are -CO-CH 3 , -CO-C 2 H 5 , -CO-C 3 H 7 , -CO-CH (CH 3 ) 2 and -CO-C (CH 3 ) 3 .
  • -NHCOC 3 H 7 -NHCO-cyclo-C 3 H 5 , -NHCO-CH (CH 3 ) 2 , -NHCO-C (CH 3 ) 3 , -NHCO-OCH 3 , -NHCO-OC 2 H 5 , -NHCO-OC 3 H 7 , -NHCO-O-cyclo-C 3 H 5 , -NHCO-OCH (CH 3 ) 2 , -NHCO-OC ⁇ CH 3 ) 3 , -NH 2 , -NHCH 3> -NHC 2 H 5 , -NHC 3 H 7 , -NH-cyclo-C 3 H 5 , -NHCH (CH 3 ) 2 , -NHC (CH 3 ) 3 , -N (CH 3 ) 2 , -N (C 2 H 5) 2l -N (C 3 H 7) 2> -N (cyclo-C 3 H 5 ⁇ 2, -N [CH (CH 3) 2] 2,
  • -C ⁇ CH 3 CH-C 2 H 5
  • -C (CH 3 ) C (CH 3 ) 2
  • -C (CH 3 ) 2 -CH CH 2 ,
  • substituents from the group of phenols methylaniline, dimethylaniline, methyl-2-aminopyridine, dimethyl-2-aminopyridine.
  • Particular preference is given to compounds having three aromatic rings which are connected to one another via vinyl bridges, resulting in extended ⁇ -electron systems.
  • Particular preference is given to compounds of the abovementioned classes with delocalized electrons via at least 15 atoms involved. More preferred are compounds having ⁇ -electron systems extending over at least 20 atoms, and particularly preferred are delocalized electron systems extending over 22 or more atoms.
  • the classification of neurodegenerative diseases is based both on the clinical presentation with typical topographic distribution and cell type of the degenerative process as well as on the deposition of structurally altered proteins such as prion protein, tau, beta-amyloid, alpha-synuclein, TDP-43 and / or Huntington.
  • the fluorescence of the substances according to the invention is either enhanced or significantly shifted when bound to the target proteins. As a result, only the necessary signal-to-noise ratio is possible.
  • diagnosis or diagnosis covers the areas of in vivo, in vitro, ex vivo diagnostics. Generally, the diagnosis or diagnosis is used exclusively or mainly to provide information.This information provides information about:
  • samples derived from the human body are used, e.g. Blood, serum, plasma, seminal fluid, spinal fluid, peritoneal fluid, saliva, sputum, tear fluid, urine, biopsy material or tissue donation. Obtaining such a sample may or may not be part of the diagnostic procedure. In certain embodiments of the present invention, obtaining the sample intended for diagnosis is not a step in the diagnostic method of the invention.
  • the compounds according to the invention are detected after binding to the Aß protein, ⁇ -synuclein and / or tau-PHF aggregates in the olfactory epithelium and / or bulb Olfactorius.
  • arylaminothiazoles 2H-indol-2-ylidene-1-propen-1-yl-indolium cations according to the invention, benzothiazolylidene-1-propenylbenzothiazolium cations, benzoxazolylidene-1-propenylbenzoxazolium cations, 4,6-divinylpyhmidines, 3,6-divinylpyridazines, 2,5-divinylpyrazines, [4- (1, 3-benzothiazol-2-yl) phenyl] hydrazones and / or diarylureas are particularly preferably used for the diagnosis of newly rodegenerativen diseases.
  • the invention comprises a method for the diagnosis of neurodegenerative diseases, a) administering at least one compound selected from the group of arylaminothiazoles, 2H-indol-2-ylidene-1-propen-1-yl-indolium cations, benzothiazolylidene-1-propenylbenzothiazolium cations,
  • the invention further encompasses a method for the in vivo detection of A ⁇ protein, ⁇ -synuclein and / or tau-PH F aggregates,
  • Divinylpyrimidines 3,6-divinylpyridazines, 2,5-divinylpyrazines, [4- (1,3-benzothiazol-2-yl) phenyl] hydrazones and diaryl ureas;
  • the compounds mentioned herein preferably act as fluorescent probes. They have a (preferably high) affinity for the Aß protein, a-synuclein and / or for tau-PH F aggregates and bind - preferably specifically - to these.
  • the binding of the compounds of the invention to one or more of the above target proteins is optically detectable.
  • the increase in absorbance upon binding to the target protein is preferably characterized by a> 10x increase in the signal-to-noise ratio improvement over the free compound, and can be determined experimentally, for example, by reducing background noise. Preference is given to compounds which have an extinction coefficient of ⁇ > 10,000 L mor 1 cm -1 .
  • the determination of the extinction coefficient or the extinction is carried out in certain embodiments at 25 ° C, pH 7, the respective absorption maximum of the compound with DMSO as solvent.
  • the difference between the excitation maximum and the emission maximum is called the Stokes shift and this value essentially determines how well a compound is suitable for fluorescence studies.
  • the compounds according to the invention are preferably characterized by a Stokes shift> 20 nm.
  • the affinity of the fluorescent probes is usually determined indirectly by the displacement of fluorescent or radioactive reference ligands.
  • the affinity of the ligands of the invention is characterized by displacement of thioflavin S, thioflavin T or 11 C-PIB with an EC50 ⁇ 300nM. This can e.g. as described in Lockhart et al., March 4, 2005, The Journal of Biologica! Chemistry, 280, 7677-7684 has been described under Material & Methods, in particular the two paragraphs "Radioligand Competition Assay” and "Fluorescence Competition Assay”.
  • the diffusivity of a compound through the endothelium of the blood-brain barrier is largely determined by its lipid solubility (lipophilicity) and size.
  • the compounds of the invention have a molecular weight ⁇ 500 g / mol.
  • the log P value and the log D value are model measures of the relationship between lipophilicity (fat solubility) and hydrophilicity (water solubility) of a substance.
  • the expectation is to be able to estimate the distribution coefficients of this substance in other systems with an aqueous and a lipophilic phase with the help of the octanol-water partition coefficient.
  • the log P value is greater than one if a substance is more soluble in fat-like solvents such as n-octanol, less than one if it is better soluble in water. Accordingly, log P value is positive for lipophilic and negative for hydrophilic substances. Preference is given to compounds which have a log P value of from 1 to 2.8.
  • compounds with a log D ⁇ 5 are preferred.
  • the measurement of the log P value or of the log D value is carried out by means of an octanol / water two-phase system and UV / VIS spectroscopy at 25 ° C. and pH 7. Since the log P value and / or the log D value can be measured, there is also other models for the prediction, eg by Quantitative Structure-Activity Relationships (QSAR) or by Linear Free Energy Relationships (LFER).
  • QSAR Quantitative Structure-Activity Relationships
  • LFER Linear Free Energy Relationships
  • the potential brain penetration of the compounds can also be defined via the topological polar surface area (TPSA or topological polar surface).
  • TPSA topological polar surface area
  • This is defined as the sum of the surface contributions of the polar atoms (usually oxygen atoms, nitrogens and / or hydrogen atoms) in one molecule.
  • the calculation was carried out, inter alia, by Ertl, P. et al., Fasting of molecular polar surface area as a sum of fragments based contributions and its application to the prediction of drug transport properties, J. Med. Chem., 2000, 43, 3714-3717. Preference is thus given in particular to compounds having a TPSA ⁇ 70 A 2 .
  • the compounds according to the invention are further characterized by good photostability (low photobleaching) and by a short-lived singlet excitation against long-lasting triplet excitation.
  • the compounds of the invention have one or more of the following physicochemical properties. Particular preference is given to compounds which have at least three of the following properties a) -f):
  • TPSA topological polar surface area
  • TPSA topological polar surface area
  • TPSA topological polar surface area
  • the compounds according to the invention have at least three of the following properties a) -f), where at least one of the properties a) and d) is selected:
  • TPSA topological polar surface area
  • the compounds according to the invention have at least three of the following properties a) -i):
  • TPSA topological polar surface area
  • the compounds disclosed herein are particularly advantageous for the early diagnosis of neurodegenerative diseases from the group of tauopathies.
  • the group of tauopathies includes neurodegenerative diseases, the common feature of which is the accumulation of the tau protein, a small molecule phosphoprotein that attaches to and regulates the assembly of supporting cytoskeletal proteins (microtubules) in the brain.
  • the compounds referred to herein are used for the early diagnosis of tauopathies, e.g. Alzheimer's disease, corticobasal degeneration, agryophilic grain disease, Pick's disease, FTDP-17 (frontotemporal dementia and parkinsonism of chromosome 17) or progressive supranuclear palsy.
  • tauopathies e.g. Alzheimer's disease, corticobasal degeneration, agryophilic grain disease, Pick's disease, FTDP-17 (frontotemporal dementia and parkinsonism of chromosome 17) or progressive supranuclear palsy.
  • the compounds according to the invention are furthermore advantageous for the early diagnosis of neurodegenerative diseases from the group of synucleinopathies.
  • the group of synucleinopathies includes neurodegenerative diseases whose common feature is the accumulation of the a-synuclein protein in the brain, e.g. Parkinson's disease.
  • the ⁇ -synuclein protein is a protein of 140 amino acids that normally occurs only in the presynaptic processes of neurons.
  • a detectable optical response is characterized in that a change or occurrence of an optical signal can be observed or measured by instruments.
  • the optical response is a change in fluorescence, such as a change in intensity, excitation or emission wavelength, fluorescence lifetime, or fluorescence polarization.
  • 3,6-divinylpyridazines, 2,5-divinylpyrazines, [4- (1, 3-benzothiazol-2-yl) phenyl] hydrazones and diarylureas can be administered systemically or locally.
  • the compounds are administered intravenously.
  • the fluorescent probes are administered parenterally.
  • the compounds are administered enterally.
  • the compounds are administered orally.
  • the compounds are administered topically nasally.
  • the compositions containing the compounds of this invention typically contain an effective concentration of the compounds in an aqueous solution or suspension which may further contain buffers, surfactants, thixotropic agents, cosolvents, flavoring agents or the like.
  • the compounds herein are preferably capable of crossing the blood-brain barrier.
  • the compounds used in the present invention may cross the blood-tissue barrier, the blood-liver barrier, the blood-cerebrospinal fluid barrier, the cerebro-spinal barrier, the blood-nerve barrier, and / or the placental barrier.
  • the disease-causing protein deposits are also located in the olfactory epithelium and / or olfactory bulb.
  • the compounds disclosed in the present application are detected after attachment to an Aß protein, ⁇ -synuclein and / or tau-PHF aggregates in the patient's olfactory epithelium and / or olfactory bulb.
  • the detection takes place by means of adaptation of the optical fiber optics or the fluorescence microscopy.
  • the detection takes place by means of suitable filter systems or detectors which are known in the prior art. Excitation in the wavelength range of 380-900 nm and emission at 400-1000 nm are preferred. The excitation between 450-500 nm and the emission at 600-650 nm or 600-700 nm is particularly preferred.
  • Alzheimer's dementia is diagnosed due to the assured absence of tau aggregates in the intestinal epithelium.
  • the thaw Aggregation in the intestinal epithelium correlates inversely with the diagnosis of Alzheimer's dementia: The lack of detection of tau aggregates with the disclosed compounds is a sure sign of Alzheimer's disease.
  • the compounds according to the invention are the following compounds:
  • BSc4090 4 - ((1E) -2- (6- (4- (dimethylamino) styrene) pyrimidin-4-yl) vinyl) -N, N-dimethylbenzenamine
  • Example 2 BSc4097: 4,4 "- (1 ⁇ , 1 ⁇ ) -2,2 '- (2- ( ⁇ 1 ⁇ ) ⁇ € ⁇ -4,6-0 ⁇ ) ⁇ 5 ( ⁇ -2 ( 1-diyl) bis ( N, N-dimethyl aniline) Synthesis: 4,6-dimethylpyrimidine-2-thiol (100 mg, 0.64 mmol), 4- ⁇ dimethylamino) benzaldehyde (193.5 mg, 1.29 mmol) and Aliquat 336 (25 mg, 0.06 mmol) are dissolved in 5M NaOH solution (10 ml). The solution is heated to boiling for 1 h at 110 ° C, then stirred for 3 h at RT. The solution is filtered and the resulting solid recrystallized from methanol (15 ml). 175 mg of BSc4097 (65%) are obtained as a yellow solid.
  • BSc4328 4,6-bis ((E) -2- (naphthalen-1-yl) vinyl) pyrimidine
  • BSc4352 4.4 , - (1 ⁇ 1 , ⁇ ) - 2,2 , - (pyrazine-2,5-diyl) bis (ethene-2,1-diyl) bis (W, W-dimethylaniline)
  • BSc4354 2,5-bis (4-methoxystyryl) pyrazine
  • Nicotinaldehyde (107 mg, 1 mmol) in tetrahydrofuran (30 mL) and NaOH (3 g, 75 mmol) are added to the reaction solution and heated at reflux for 3 h. The cooled reaction solution is washed twice with water, dried over Na 2 SO 4 and the solvent removed in vacuo. After purification by column chromatography (1: 1 EtOAc / hexane, silica gel) 257 mg, (77.9%) of BSc4337 are obtained.
  • BSc4007 W- (4- (7- (Diethylamino) -2-oxo-2H-chromen-3-yl) thiazol-2-yl) nicotinohydrazide
  • 6-Substituted 1-methyl-2-PEG-benzo [d] thiazole-3-ium 6-substituted 2-methylbenzo [d] thiazole (5 mmol) is dissolved in a 10 mL flask containing 2-methoxyethyl-4-toluenesulfonates ( 6 mmol). The reaction mixture is heated under argon atmosphere to 120 ° C and stirred for 12 hours, whereby the reaction mixture turns violet. Allow to cool to room temperature. The resulting precipitate is recrystallized from ethyl acetate to give 6-substituted 1-methyl-2-PEG-benzo [d] thiazole-3-ium colorless solid.
  • Example 21 Staining protocol for the compounds of the invention
  • tissue samples were fixed in 10% buffered formalin solution and embedded in paraffin. At the microtome 4 ⁇ thick sections were made and mounted in a water bath on slides. The deparaffination took place via the following steps:
  • the dyes according to the invention were dripped onto the tissue section from 0.01-1% ethanolic or methanolic solution (50-200 ⁇ l) and incubated in a moist, EtOH / MeOH saturated and light-protected chamber for 10 minutes.
  • a moist, EtOH / MeOH saturated and light-protected chamber for 10 minutes.
  • up to 10% DMSO was added and optionally filtered through a syringe filter (0.45pm pore size).
  • Example 23 The samples were stained with the dyes of the present invention as described in Example 21 and then examined with a Zeiss Axioskop, ABO 100Hg Fluore, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX. Depending on the dye used, either a FITC filter or a DAPI filter was used. The results can be seen in FIGS. 1 to 21 and show the binding and visualization of the dyes according to the invention.
  • Example 23 Example 23:
  • the affinity of the compounds according to the invention was checked by means of a radioligand competition assay.
  • Aß- (1-42) - peptide was incubated in a concentration of 10 mg / ml in PBS with 0.1% BSA together with [125 I] IMPY 0.1 nM and different concentrations of the ligand for 3 h at 20 ° C and then by a Whatman GF / B filters filtered.
  • FIG. 1 staining with BSc4258 human olfactory epithelium, patient AD +; Tau aggregates,
  • FITC-filter Zeiss Axioskop, ABO lOOHg fluorescent lamp, camera: Leica DFC300FX
  • Figure 2 staining with BSc4258 human brain tissue, patient AD +; amyloid
  • Plaque Plaque
  • FITC filter Zeiss Axioskop
  • ABO 100Hg fluorescent lamp camera: Leica DFC300FX
  • Figure 3 Staining with BSc4090 Ammonium horn, male 89J, AD +, A ⁇ plaque, FITC filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 4 Staining with BSc4090 Ammonium horn, male 89J, AD +, A ⁇ plaque, DAPI filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 5 Staining with BSc4097 Ammonium horn, male 89J, AD +, A ⁇ plaque, DAPI filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica
  • Figure 6 staining with BSc4097 Ammonium horn, male 89J, AD +, A ⁇ plaque
  • Figure 7 Staining with BSc4327 Ammonium horn, male 82J, AD +, Aß in one
  • Angiopathy FITC filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 8 Staining with BSc4328 Ammonshorn, male 82J, AD +, Aß plaque, DAPI filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 9 Staining with BSc4352 Ammonshorn, male 82J, AD +, A ⁇ plaque, DAPI filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 10 Staining with BSc4352 Ammonium horn, male 82J, AD +, A ⁇ plaque, DAPI filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica
  • Figure 11 Staining with BSc4353 Ammonium horn, male 82J, AD +, A ⁇ in one
  • Figure 13 Staining with BSc4354 Ammonium horn, male 82J, AD +, A ⁇ in one
  • Angiopathy FITC filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp,
  • Figure 14 staining with BSc4354 ammone horn, male 89J, AD +, A ⁇ plaque, FITC filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 15 Staining with BSc4342 Ammonshorn, male 89J, AD +, A ⁇ plaque, DAPI fiiter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 16 Staining with BSc4342 Ammonshorn, male 89J, AD +, A ⁇ plaque, DAPI filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 17 Staining with BSc4337 Ammonshorn, male 89J, AD +, A ⁇ plaque, DAPI filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX
  • Figure 18 Staining with BSc4337 Ammonshorn, male 89J, AD +, A ⁇ plaque, DAPI filter, Zeiss Axioscope, ABO 100Hg fluorescent lamp, camera: Leica
  • FIG. 19 staining with BSc4007 ammone horn, male 89J, AD, tau fibril,
  • FIG. 20 staining with BSc4138 ammone horn, male 89J, AD, tau fibril,
  • Figure 21 Staining with BSc4138 Ammonium horn, male 89J, AD, A ⁇ plaque, DAPI filter; Zeiss Axioskop, ABO 100Hg fluorescent lamp, camera: Leica DFC300FX)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La présente invention concerne des composés ayant une haute affinité pour la protéine Aß, l'α-synucléine ou pour l'agrégat Tau-PHF, lesquels conviennent comme sondes de préférence fluorescentes pour le diagnostic in vivo de maladies neurodégénératives, comme par exemple la démence d'Alzheimer ou le Morbus Parkinson. Les composés se distinguent par des propriétés physico-chimiques appropriées (longueur d'onde d'excitation, longueur d'onde d'émission, déplacement de Stokes, extinction) ainsi que par une haute affinité et une haute sélectivité vis-à-vis des protéines cibles.
EP11804933.7A 2010-09-20 2011-09-20 Composés pour le diagnostic de maladies neurodégénératives sur l'épithélium olfactif Withdrawn EP2619591A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010045797A DE102010045797A1 (de) 2010-09-20 2010-09-20 Verbindungen für die Diagnostik neurodegenerativer Erkrankungen am Riechepithel
PCT/DE2011/001780 WO2012037928A2 (fr) 2010-09-20 2011-09-20 Composés pour le diagnostic de maladies neurodégénératives sur l'épithélium olfactif

Publications (1)

Publication Number Publication Date
EP2619591A2 true EP2619591A2 (fr) 2013-07-31

Family

ID=45445673

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11804933.7A Withdrawn EP2619591A2 (fr) 2010-09-20 2011-09-20 Composés pour le diagnostic de maladies neurodégénératives sur l'épithélium olfactif

Country Status (4)

Country Link
US (1) US20130287700A1 (fr)
EP (1) EP2619591A2 (fr)
DE (1) DE102010045797A1 (fr)
WO (1) WO2012037928A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6257612B2 (ja) * 2012-07-04 2018-01-10 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ヒドラゾン部分を含有する有機色素及びそれらの色素増感太陽電池における使用
US11813338B2 (en) * 2013-03-12 2023-11-14 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
US10662193B2 (en) 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
CN104531139B (zh) * 2015-01-06 2016-06-22 山西大学 一种咔唑类的pH荧光探针及其制备方法和应用
US9862682B2 (en) 2016-01-08 2018-01-09 BroadPharm Functionalized pegylated cyanine compounds, pharmaceutical compositions, and methods of use thereof
CN109071528B (zh) 2016-03-11 2023-02-17 Ac免疫有限公司 用于诊断和治疗的双环化合物
EP3677569A4 (fr) * 2017-08-31 2021-05-19 Sanko Co., Ltd. Dérivé de n,n'-diarylurée, son procédé de fabrication, et matériau d'enregistrement thermosensible l'utilisant
WO2019126565A1 (fr) * 2017-12-20 2019-06-27 The Regents Of The University Of Colorado, A Body Corporate Dérivés lipidiques pour administration in vitro ou in vivo
CA3102038A1 (fr) 2018-06-08 2019-12-12 Ac Immune Sa Nouveaux composes pour diagnostic
CN110054587B (zh) * 2019-05-31 2020-11-03 浙江工业大学 一种具有AIE特征的pH荧光化合物及其制备与应用
IL297965A (en) 2020-05-07 2023-01-01 Ac Immune Sa New compounds for diagnosis
WO2023083998A1 (fr) 2021-11-10 2023-05-19 Ac Immune Sa Dérivés du dihydropyrrolo[3,4c]-pyrazole et leur utilisation à des fins de diagnostic
MX2024005426A (es) 2021-11-10 2024-05-21 Ac Immune Sa Derivados de 4h-imidazo[1,5-b]pirazol para diagnostico.
EP4430044A1 (fr) 2021-11-10 2024-09-18 AC Immune SA Dérivés du dihydropyrrolo[3,4-c]pyrazole et leur utilisation à des fins de diagnostic
WO2024126840A1 (fr) 2022-12-16 2024-06-20 Ac Immune Sa Nouveaux composés pour diagnostic
WO2024126842A1 (fr) 2022-12-16 2024-06-20 Ac Immune Sa Nouveaux composés pour diagnostic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260757A (en) * 1979-07-18 1981-04-07 Wiley Richard H Poly[di-1,2-(diazinylidene)-ethene-1,2-diols]
JPS57134417A (en) * 1981-02-14 1982-08-19 Meiji Seika Kaisha Ltd Cardiotonic agent
US7297326B2 (en) * 2000-08-21 2007-11-20 The General Hospital Corporation Ocular diagnosis of Alzheimer's disease
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US7597878B2 (en) 2000-09-19 2009-10-06 Li-Cor, Inc. Optical fluorescent imaging
WO2004041266A1 (fr) * 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Agent de controle de la fonction recepteur
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
ES2554772T3 (es) 2008-05-30 2015-12-23 Merck Sharp & Dohme Corp. Azabenzoxazoles sustituidos novedosos
KR101095026B1 (ko) * 2009-01-23 2011-12-20 한국과학기술연구원 비스(스티릴)피리미딘 및 비스(스티릴)벤젠 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012037928A2 *

Also Published As

Publication number Publication date
WO2012037928A2 (fr) 2012-03-29
DE102010045797A1 (de) 2012-03-22
WO2012037928A3 (fr) 2013-04-25
US20130287700A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
EP2619591A2 (fr) Composés pour le diagnostic de maladies neurodégénératives sur l'épithélium olfactif
US7700616B2 (en) Compounds and amyloid probes thereof for therapeutic and imaging uses
DE60012742T2 (de) Inhibition von amyloid protein aggregation und bilderzeugung von amyloidniederschlägen mit isoindolderivate
JP4247123B2 (ja) バイオマーカーとして有用なクマリン
JP6194416B2 (ja) タウ−ｐｅｔリガンドとしてのジアザカルバゾール誘導体
RU2671506C2 (ru) Имидазо[1,2-а]пиридин-7-амины в качестве средств визуализации
DE60103394T2 (de) 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung
EP2619590A2 (fr) Composés pour le diagnostic de maladies neurodégénératives sur la rétine
JP7260552B2 (ja) Ｐｅｔ画像化のための診断用組成物、診断用組成物を製造するための方法及び診断におけるその使用
DE60103054T2 (de) Phenyloxazol-1,4-diazabicyclo[3.2.2]nonanderivate, ihre herstellung und ihre therapeutische verwendung
DE69106746T2 (de) Imidazo[1,2-c]chinazolinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
CN107949383B (zh) 用于成像的含氮氧化合物的淀粉样蛋白结合剂
JP6228980B2 (ja) アルツハイマー病の診断薬として有用なイミダゾ［２，１］チアゾール−３−オン誘導体
DE68903680T2 (de) 6-phenyl-3-piperazinylalkyl-1h,3h-pyrimidindion-2,4-derivate, deren herstellung und verwendung als heilmittel.
CN109180556B (zh) 一种部花菁类荧光化合物及其制备方法和应用
JP2021512064A (ja) 画像化化合物を調製する新規方法
JP3877754B2 (ja) アミロイド親和性化合物
KR102344676B1 (ko) 타우 응집체에 선택적으로 결합하는 근적외선 형광 탐침자로서 유효한 신규 화합물 및 이의 제조방법
DE60115569T2 (de) Phenoxazinanaloge zur Behandlung von Amyloidose
DE69015220T2 (de) Glycocyamidin-Derivate.
WO2018164184A1 (fr) Agent d'imagerie diagnostique et agent de diagnostic extracorporel pour des maladies neurologiques incurables
DE602004004280T2 (de) Als mittel zur nahinfrarotabbildung geeignete 3h-phenoxazinderivate, deren herstellung und verwendung
EP2890700B1 (fr) Dérivés halogénés de benzoxazine et leur utilisation
WO2014032732A1 (fr) Benzoxazine halogénée et son utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17P Request for examination filed

Effective date: 20131025

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140520